INTRODUCTION
STUDY GOALS AND OBJECTIVES
The aim of this report is to provide detailed market, technology and industry analyses to help readers quantify and qualify the market for prescription generic drugs used in the treatment of diabetes and devices and instruments used for diagnosis and monitoring of diabetes. Important trends are identified and sales forecasts by product categories and major country markets are provided through 2015; these are based on epidemiological data and projections, plus information on R&D trends and differential market potential on a country-by-country basis. Healthcare policies, demographics, and the wider economic environment are also taken into account.
REASONS FOR DOING THE STUDY
It is widely recognized that the prevalence of the commonest type of diabetes mellitus, Type 2, is now reaching epidemic proportions all over the world. Cases of Type 1 DM are also on the increase, although to a less spectacular degree. These trends are of great concern, not only to the individuals concerned, but to governments and providers of healthcare, because the economic consequences of diabetes are vast, as they involve not only the direct burden of managing the disease but also the common and often catastrophic complications including cardiovascular disease, peripheral neuropathy and blindness.
Thus the prompt diagnosis and effective treatment of diabetes are essential, not optional, priorities for governments and healthcare agencies. One consequence is that the already large market for diabetes monitoring and treatment will certainly grow in line with increasing incidence and with improvements in diagnosis. Thus diabetes is of great commercial significance to the suppliers of drugs used in treatment and devices needed for monitoring.
Among the information needs of companies in this field is accurate and up-to-date assessment of the current extent of the diabetes epidemic, its likely evolution over the next 5 years, and the impact of drugs and technical developments now in the pipeline.
SCOPE OF REPORT
This report discusses the implications of the above-mentioned trends, in the context of the current size and growth of the diabetes market, both in global terms and analyzed by the most important national markets. Companies in the relevant pharmaceutical and medical industries are discussed, with profiles of the leaders and an update on M&A activity. Five-year global sales forecasts are provided for main drug and device categories, and breakdowns are provided for several national markets.
MARKET ANALYSIS AND FORECASTS
Market figures are based on revenues at the manufacturer level and are projected at 2010-dollar value without attempting to predict the effect of inflation/deflation.
Therapeutic categories quantified and forecast include insulins and oral hypoglycemic agents, and devices including blood glucose monitors and accessories.
METHODOLOGY
Primary research includes interviews with leading individuals in relevant companies and medical associations; primary sources of published data include epidemiological and economic studies, company annual reports, SEC filings, and government publications. Secondary sources consist of literature searches, industry journals, and other commercial publications. Data for market estimates and forecasts are pooled from a range of sources, critically assessed by BCC.
INTENDED AUDIENCE
This report is designed to satisfy the information needs of a wide variety of individuals involved in the diabetes marketplace, including company senior management executives seeking to base their strategic decisions on the best available information on market forces and trends. However, it is also aimed at managers and executives in marketing, research, planning, and sales departments who need readable, comprehensive and up-to-date background on the marketplace in which they are operating.
INFORMATION SOURCES
Sources of information included marketing strategists, industry executives, government and professional agencies, and surveys of physicians. Company annual reports and SEC filings, journal articles, and data from healthcare institutions were also mined, as well as publications of relevant associations such as the International Diabetes Federation and the American and British Diabetic Associations.
ANALYST CREDENTIALS
Paul Evers has been involved in analyzing pharmaceutical and medical markets for 20 years. He is the author of previous reports on the diabetes marketplace covering both therapeutic and monitoring aspects.
BCC ONLINE SERVICES
BCC offers an online information retrieval service. BCC’s home page, located at www.bccresearch.com, enables readers to:
- Examine BCC’s complete catalog of Market Research Reports and place direct orders
- Subscribe to any of BCC’s many industry newsletters
- Read announcements of recently published reports and newly launched newsletters
- Register for BCC’s well-known conferences
- Request additional information on any BCC product
- Take advantage of special offers
DISCLAIMER
The information developed in this report is intended to be as reliable as possible at the time of publication and of a professional nature. This information does not constitute managerial, legal, or accounting advice; nor should it serve as a corporate policy guide, laboratory manual, or an endorsement of any product, as much of the information is speculative in nature. The author assumes no responsibility for any loss or damage that might result from reliance on the reported information or its use.
Report Code: HLC029C, Published: June 2010, Analyst: Paul Evers
